Patent ID: 9669010
Date: 2017-06-06
CPC Classifications: A61K

Claim:
1. A composition suitable for enteral administration for use in treating chronic kidney disease in mammals, wherein the composition consists of: between 8% and 30% by weight glycine; between 8% and 30% by weight L-aspartic acid and/or salts thereof; between 8% and 30% by weight L-glutamic acid and/or salts thereof; between 8% and 30% by weight L-glutamine; between 3% and 15% by weight L-histidine; between 3% and 15% by weight L-arginine; and between 8% and 30% by weight L-carnosine, based on the total weight of composition, wherein the L-glutamic acid and/or salts thereof is present in a particulate form having a particle size of less than or equal to 320 mesh.